{
    "nct_id": "NCT05141721",
    "official_title": "A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer",
    "inclusion_criteria": "* Patients with histologically confirmed metastatic colorectal cancer (CRC) who are planned for, or have received <30 days of first-line treatment in the metastatic setting with FOLFOX/bev, CAPEOX/bev, FOLFOXIRI/bev, or CAPOXIRI/bev per SOC\n* Measurable and unresectable metastatic disease according to RECIST v1.1\n* Availability of formalin-fixed paraffin-embedded (FFPE) tumor specimens.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Patient has adequate organ function per defined criteria\n* If women of childbearing potential (WCBP), must be willing to undergo pregnancy testing and agrees to the use at least 1 highly effective contraceptive method during the study treatment period and for 150 days after last investigational study treatment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with deficient mismatch repair (dMMR) or microsatellite instability (MSI-H) phenotype\n* Patient has a known tumor mutation burden <1 non-synonymous mutations/megabase\n* Known DNA Polymerase Epsilon mutations\n* Patients with known BRAFV600E mutations\n* Bleeding disorder or history of significant bruising or bleeding following IM injections or blood draws\n* Immunosuppression anticipated at time of study treatment\n* History of allogeneic tissue/solid organ transplant\n* Active or history of autoimmune disease or immune deficiency\n* Patient with symptomatic or actively progressing central nervous system (CNS) metastases, carcinomatous meningitis, or has been treated with whole brain radiation\n* History of other cancer within 2 years with the exception of neoplasm that has undergone potentially curative therapy\n* Any severe concurrent non-cancer disease that, in the judgment of the Investigator, would make the patient inappropriate for the current study\n* Active tuberculosis or recent (<2 weeks) clinically significant infection, evidence of active hepatitis B or hepatitis C, or known history of positive test for HIV\n* History of pneumonitis requiring systemic steroids for treatment (with the exception of prior resolved in-field radiation pneumonitis)\n* Myocardial infarction within previous 3 months, unstable angina, serious uncontrolled cardiac arrhythmia, history of myocarditis, or congestive heart failure (Class III or IV).\n* Pregnant, planning to become pregnant, or nursing.",
    "miscellaneous_criteria": ""
}